doi: 10.1161/hq0901.095545
© 2001 American Heart Association, Inc.
Atherosclerosis and Lipoproteins |
Coronary Artery Complicated Lesion Area Is Related to Functional Polymorphism of Matrix Metalloproteinase 9 Gene
An Autopsy Study
From the Laboratory of Atherosclerosis Genetics (P.J.P., P.J.K., K.M.M., T.K., T.L.), Department of Clinical Chemistry, Centre for Laboratory Medicine, Tampere University Hospital; the Department of Forensic Medicine (P.J.K., J.M.), Medical School, University of Tampere; and the Tampere School of Public Health (P.L.), University of Tampere and Research Unit, Tampere University Hospital, Tampere, Finland; the Department of Forensic Medicine (A.P.), University of Helsinki, and the Department of Human Molecular Genetics, National Public Health Institute, Helsinki, Finland; and the Department of Human Genetics (M.P.), University of California, Los Angeles.
Correspondence to Terho Lehtimäki, MD, PhD, Laboratory of Atherosclerosis Genetics, Finn Medi 2, Department of Clinical Chemistry, Center for Laboratory Medicine, Tampere University Hospital, PO Box 2000, 33521 Tampere, Finland. E-mail bltele{at}uta.fi
Abstract—— Matrix metalloproteinase 9 (MMP9) is expressed in human atherosclerotic plaques, and the protein is localized in human coronary atherosclerotic lesions. The MMP9 gene has a C-to-T promoter polymorphism at position -1562, which affects transcription and leads to promoter low-activity (C/C) and high-activity (C/T, T/T) genotypes. To determine whether these genotypes exert an influence on the atherosclerotic lesion area, we investigated their association with different types of coronary lesions in an autopsy cohort of 276 men aged 33 to 69 years. Areas of the coronary wall covered with fatty streaks and fibrotic, calcified, and complicated lesions were measured, and the percentage of coronary narrowing was determined. MMP9 genotypes were determined by polymerase chain reaction and restriction enzyme digestion. In men aged 
53 years, the mean area of complicated lesions in 3 coronaries was significantly associated with the MMP9 genotype (P=0.008). Subjects with high promoter activity genotypes had, on average, larger complicated lesion areas than did those with the low-activity genotype. The MMP9 genotype persisted as an independent predictor of complicated lesion area after adjustment for age, body mass index, hypertension, diabetes, and smoking (P=0.012). These data provide evidence that the proposed effect of MMP9 in the process of atherosclerotic lesion development may be modified by the MMP9 genotype.
Key Words: matrix metalloproteinase 9 • coronary artery disease • complicated lesions • genetics • polymorphism
This article has been cited by other articles:
 |
|
 |
|
  S. Abilleira, S. Bevan, and H. S Markus The role of genetic variants of matrix metalloproteinases in coronary and carotid atherosclerosis J. Med. Genet., December 1, 2006; 43(12): 897 - 901. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-o Deguchi, M. Aikawa, C.-H. Tung, E. Aikawa, D.-E. Kim, V. Ntziachristos, R. Weissleder, and P. Libby Inflammation in Atherosclerosis: Visualizing Matrix Metalloproteinase Action in Macrophages In Vivo Circulation, July 4, 2006; 114(1): 55 - 62. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Fiotti, N. Altamura, M. Fisicaro, N. Carraro, L. Uxa, G. Grassi, L. Torelli, R. Gobbato, G. Guarnieri, B. T. Baxter, et al. MMP-9 Microsatellite Polymorphism and Susceptibility to Carotid Arteries Atherosclerosis Arterioscler Thromb Vasc Biol, June 1, 2006; 26(6): 1330 - 1336. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ye Influence of matrix metalloproteinase genotype on cardiovascular disease susceptibility and outcome Cardiovasc Res, February 15, 2006; 69(3): 636 - 645. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. de Nooijer, C.J.N. Verkleij, J.H. von der Thusen, J.W. Jukema, E.E. van der Wall, Th. J.C. van Berkel, A.H. Baker, and E.A.L. Biessen Lesional Overexpression of Matrix Metalloproteinase-9 Promotes Intraplaque Hemorrhage in Advanced Lesions But Not at Earlier Stages of Atherogenesis Arterioscler Thromb Vasc Biol, February 1, 2006; 26(2): 340 - 346. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Shan, Z. Lian-Fu, D. Hui, G. Wei, W. Na, J. Xia, and L. Yan Polymorphisms in the promoter regions of the matrix metalloproteinases-7, -9 and the risk of endometriosis and adenomyosis in China Mol. Hum. Reprod., January 1, 2006; 12(1): 35 - 39. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. C. Newby and J. L. Johnson Genetic Strategies to Elucidate the Roles of Matrix Metalloproteinases in Atherosclerotic Plaque Growth and Stability Circ. Res., November 11, 2005; 97(10): 958 - 960. [Full Text] [PDF]
|
|
|
|
 |
|
 F Lose, P J Thompson, D Duffy, G A Stewart, and M-A Kedda A novel tissue inhibitor of metalloproteinase-1 (TIMP-1) polymorphism associated with asthma in Australian women Thorax, August 1, 2005; 60(8): 623 - 628. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Hulkkonen, M. Pertovaara, J. Antonen, A. Pasternack, M. Hurme, P. Pollanen, and T. Lehtimaki Matrix metalloproteinase 9 (MMP-9) gene polymorphism and MMP-9 plasma levels in primary Sjogren's syndrome Rheumatology, December 1, 2004; 43(12): 1476 - 1479. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. L. Medley, T. J. Cole, A. M. Dart, C. D. Gatzka, and B. A. Kingwell Matrix Metalloproteinase-9 Genotype Influences Large Artery Stiffness Through Effects on Aortic Gene and Protein Expression Arterioscler Thromb Vasc Biol, August 1, 2004; 24(8): 1479 - 1484. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Blankenberg, H. J. Rupprecht, O. Poirier, C. Bickel, M. Smieja, G. Hafner, J. Meyer, F. Cambien, L. Tiret, and for the AtheroGene Investigators Plasma Concentrations and Genetic Variation of Matrix Metalloproteinase 9 and Prognosis of Patients With Cardiovascular Disease Circulation, April 1, 2003; 107(12): 1579 - 1585. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. M. Thompson and I. B. Squire Matrix metalloproteinase-9 expression after myocardial infarction: physiological or pathological? Cardiovasc Res, June 1, 2002; 54(3): 495 - 498. [Full Text] [PDF]
|
|